Abstract
Three new 18F labeled fluoroalkyl tyrosine derivatives, O-(2-[18F]fluoroethyl)-α-methyltyrosine (FEMT, [18F]2), O-(2-[18F]fluoroethyl)-2-l-azatyrosine (FEAT, [18F]3), O-(2-[18F]fluoroethyl)-l-tyrosineamide (FETA, [18F]4) have been synthesized and radiofluorinated with 5–34% decay-corrected yield. In vitro studies were carried out in U-138 MG human glioblastoma. Cellular uptake of new tracers was compared to clinically utilized imaging agent O-(2-[18F]fluoroethyl)-l-tyrosine (FET, [18F]1). The uptake of tracers followed the order of FET ([18F]1)>FEAT([18F]3)>FEMT ([18F]2)≈FETA ([18F]4).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
